At CD BioSciences, we recognize that navigating the landscape of herpesvirus (HHV)-related research can be complex. To support our clients in the pharmaceutical, biotech, and academic sectors, we have compiled answers to frequently asked questions regarding our services, products, technology platforms, and operational practices. This page is divided into general and technical categories for easier reference.
General FAQs
Q1: What does CD BioSciences specialize in?
A: CD BioSciences focuses exclusively on human herpesvirus (HHV)-related research, offering specialized products, services, and solutions tailored to the needs of drug developers, academic researchers, and biotech companies. We operate within the research and preclinical development stages and do not provide clinical-stage services or products for personal use.
Q2: Are your products and services available globally?
A: Yes. While our primary client base is located in North America and Europe, we provide global support and shipping for HHV research materials. All products are intended strictly for research use and are not available for individual or clinical application.
Q3: What types of clients do you serve?
A: Our clients include pharmaceutical companies, vaccine developers, academic research institutions, CROs, and biotechnology firms engaged in early-stage HHV research and development.
Q4: Can you develop custom assays or models for specific herpesviruses?
A: Absolutely. We offer customizable solutions across multiple HHV species—including HSV-1, HSV-2, VZV, CMV, EBV, and KSHV. Our platforms support virus engineering, infection modeling, latency establishment, and in vivo studies tailored to specific project goals.
Q5: Are your services compliant with regulatory expectations for preclinical research?
A: Yes. While we are not a GLP-certified facility, our preclinical study designs align with IND-enabling research expectations and are supported by robust documentation suitable for regulatory submissions when applicable.
Technical FAQs
Q1: What antiviral screening formats does CD BioSciences offer?
A: We provide high-throughput screening formats, including plaque reduction assays, cytopathic effect (CPE) inhibition assays, qPCR-based viral load quantification, and luciferase reporter assays. These are adapted for both wild-type and engineered herpesviruses.
2: Can I test my compound against drug-resistant HHV strains?
A: Yes. Our viral reagent collection includes resistant strains of HSV and CMV. We also provide engineered strains with specific polymerase or helicase-primase mutations for mechanistic or resistance profiling studies.
3: What controls are included in your antiviral screening assays?
A: Standard-of-care antivirals (e.g., acyclovir, ganciclovir, foscarnet) are included as positive controls. Cytotoxicity is evaluated using parallel cell viability assays to ensure selectivity index calculation.
4: Do you support MoA studies for lead compounds?
A: Yes. We offer mechanism-of-action (MoA) elucidation through time-of-addition studies, resistance passaging, biochemical assays targeting viral enzymes (e.g., polymerase, helicase), and viral entry inhibition assays.
5: How are viral titers quantified in in vivo studies?
A: Viral burden is quantified using qPCR, plaque assay, or luciferase imaging (if reporter viruses are used), depending on the virus type and model. We tailor the quantification method based on the study design and desired sensitivity.
Need More Help?
If your question is not listed above or if you need more in-depth consultation regarding your project, feel free to contact our scientific support team or explore our technology platforms and services overview pages for detailed information.
Why This FAQ Matters
By addressing the most common inquiries from our clients, we aim to foster transparency, build trust, and streamline the project onboarding process. Our commitment to scientific excellence, regulatory awareness, and herpesvirus specialization ensures that our partners receive the support they need at every step of their R&D pipeline.
